ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Data Note

A guide to selecting high-performing antibodies for S1PR1 (UniProt ID: P21453) for use in western blot, immunoprecipitation, and immunofluorescence

[version 1; peer review: 1 not approved]
PUBLISHED 11 Jul 2024
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the YCharOS (Antibody Characterization through Open Science) gateway.

Abstract

Sphingosine 1-phosphate receptor 1 (S1PR1) is a G-coupled protein receptor that induces crucial biological processes when bound by sphingosine 1-phosphate. Here, we have characterized nine S1PR1 commercial antibodies for western blot, immunoprecipitation, and immunofluorescence using a standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls. These studies are part of a larger, collaborative initiative seeking to address antibody reproducibility issues by characterizing commercially available antibodies for human proteins and publishing the results openly as a resource for the scientific community. While use of antibodies and protocols vary between laboratories, we encourage readers to use this report as a guide to select the most appropriate antibodies for their specific needs.

Keywords

UniProt ID P21453, S1PR1, sphingosine 1-phosphate receptor 1, EDG1, antibody characterization, antibody validation, western blot, immunoprecipitation, immunofluorescence

Introduction

Sphingosine 1-phosphate receptor 1 (S1PR1), is a G-protein coupled receptor which binds to its abundant ligand, sphingosine 1-phosphate, inducing intracellular signalling pathways in cell growth, differentiation, migration and trafficking.14 S1PR1 activation by sphingosine 1-phosphate is essential for neuronal events, and its dysregulation may contribute to the pathogenesis of Alzheimer’s disease.5,6 High-performing S1PR1 antibodies would facilitate S1PR1 research and uncover therapeutic strategies.

This research is part of a broader collaborative initiative in which academics, funders and commercial antibody manufacturers are working together to address antibody reproducibility issues by characterizing commercial antibodies for human proteins using standardized protocols, and openly sharing the data.79 Here we evaluated the performance of nine commercial antibodies for S1PR1 for use in western blot, immunoprecipitation, and immunofluorescence, enabling biochemical and cellular assessment of S1PR1 properties and function. The platform for antibody characterization used to carry out this study was endorsed by a committee of industry and academic representatives. It involves identifying appropriate cell lines with adequate target protein expression, developing or contributing equivalent knockout (KO) cell lines and finally, characterizing most commercially available antibodies against the corresponding target protein. The standardized antibody characterization protocols are openly available on Protocol Exchange (DOI: 10.21203/rs.3.pex-2607/v1).10

The authors do not engage in result analysis or offer explicit antibody recommendations. A limitation of this study is the use of universal protocols - any conclusions remain relevant within the confines of the experimental setup and cell line used in this study. Our primary aim is to deliver top-tier data to the scientific community, grounded in Open Science principles. This empowers experts to interpret the characterization data independently, enabling them to make informed choices regarding the most suitable antibodies for their specific experimental needs. Guidelines on how to interpret antibody characterization data found in this study are featured on the YCharOS gateway.11

Results and discussion

Our standard protocol involves comparing readouts from WT (wild type) and KO cells.12,13 The first step is to identify a cell line(s) that expresses sufficient levels of S1PR1 to generate a measurable signal using antibodies. To this end, we examined the DepMap transcriptomics database to identify all cell lines that express the target at levels greater than 2.5 log2 (transcripts per million “TPM” + 1), which we have found to be a suitable cut-off (Cancer Dependency Map Portal, RRID:SCR_017655). The SK-HEP-1 cells expresses the S1PR1 transcript at 6.5 log2 (TPM+1) RNA levels, which is above the average range of cancer cells analyzed. Parental and S1PR1 KO SK-HEP-1 cells were obtained from Abcam (Table 1).

Table 1. Summary of the cell lines used.

InstitutionCatalog numberRRID (Cellosaurus)Cell lineGenotype
ATCCHTB-52CVCL_0525SK-HEP-1WT
Abcam--SK-HEP-1S1PR1 KO

For western blot experiments, WT and S1PR1 KO protein lysates were rain on SDS-PAGE, transferred onto nitrocellulose membranes, and then probed with nine S1PR1 antibodies in parallel (Table 2, Figure 1).

Table 2. Summary of the S1PR1 antibodies tested.

CompanyCatalog numberLot numberRRID (Antibody Registry)ClonalityClone IDHostConcentration (μg/μl)Vendors recommended applications
Abcamab233386**GR3404607-2AB_2928162recombinant-monoEPR21202rabbit0.43Wb
ABclonalA1293559370101AB_2759781polyclonal-rabbit1.10Wb
Aviva Systems BiologyARP80838QC56393-190325AB_3083071polyclonal-rabbit0.50Wb
Novus Biologicals (a Bio-Techne brand)NBP2-67129**HN1019AB_3083072recombinant-monoJM10-66rabbit1.00Wb, IF
Cell Signaling Technology63335**1AB_3083073recombinant-monoE8U3Orabbit0.20Wb, IP, IF
Proteintech55133-1-AP89828AB_10793721polyclonal-rabbit1.00Wb, IP
Thermo Fisher ScientificMA5-32587**XC3523726AB_2809864recombinant-monoJM10-66rabbit1.00Wb, IF
Thermo Fisher ScientificMA5-35431**XC3523881AB_2849332recombinant-monoARC0881rabbit0.29Wb
Thermo Fisher ScientificMA5-38484*XC3523353AB_2898397monoclonal8EAH5mouse1.00Wb

* Monoclonal antibody.

** Recombinant antibody.

12a23fd0-982c-43a5-8a6b-bdaddff3e4c2_figure1.gif

Figure 1. S1PR1 antibody screening by western blot.

Lysates of SK-HEP-1 (WT and S1PR1 KO) were prepared and 30 μg of protein were processed for western blot with the indicated S1PR1 antibodies. The Ponceau stained transfers of each blot are presented to show equal loading of WT and KO lysates and protein transfer efficiency from precast midi 4-20% Tris-Glycine polyacrylamide gel (Thermo Fisher Scientific, cat number WXP42012BOX) to the nitrocellulose membrane. Antibody dilutions were chosen according to the recommendations of the antibody supplier. Antibody dilution used: ab233386** at 1/1000, A12935 at 1/1000, ARP80838 at 1/500., NBP2-67129** at 1/1000, 63335** at 1/1000, 55133-1-AP at 1/1000, MA5-32587** at 1/1000, MA5-35431** at 1/1000, MA5-38484* at 1/500. Predicted band size: 42.8 kDa. *Monoclonal antibody, **Recombinant antibody.

We then assessed the capability of all nine antibodies to capture S1PR1 from SK-HEP-1 protein extracts using immunoprecipitation techniques, followed by western blot analysis. For the immunoblot step, a specific S1PR1 antibody identified previously (refer to Figure 1) was selected. Equal amounts of the starting material (SM), the unbound fraction (UB), as well as the whole immunoprecipitate (IP) eluates were separated by SDS-PAGE (Figure 2).

12a23fd0-982c-43a5-8a6b-bdaddff3e4c2_figure2.gif

Figure 2. S1PR1 antibody screening by immunoprecipitation.

SK-HEP-1 lysates were prepared, and immunoprecipitation was performed using 2.0 μg of the indicated S1PR1 antibodies pre-coupled to Dynabeads protein A or protein G. Samples were washed and processed for western blot on a precast midi 4-20% Tris-Glycine polyacrylamide gel with the indicated S1PR1 antibodies. For western blot, ab233386** was used at 1/1000. The Ponceau stained transfers of each blot are shown. SM = 4% starting material; UB = 4% unbound fraction; IP = immunoprecipitate, HC = antibody heavy chain, LC = antibody light chain. *Monoclonal antibody, **Recombinant antibody.

For immunofluorescence, nine antibodies were screened using a mosaic strategy. First, SK-HEP-1 WT and S1PR1 KO cells were labelled with different fluorescent dyes in order to distinguish the two cell lines, and the S1PR1 antibodies were evaluated. Both WT and KO cells were imaged in the same field of view to reduce staining, imaging and image analysis bias (Figure 3). Quantification of immunofluorescence intensity in hundreds of WT and KO cells was performed for each antibody tested,10 and the images presented in Figure 3 are representative of this analysis.

12a23fd0-982c-43a5-8a6b-bdaddff3e4c2_figure3.gif

Figure 3. S1PR1 antibody screening by immunofluorescence.

SK-HEP-1 WT and S1PR1 KO cells were labelled with a green or a far-red fluorescent dye, respectively. WT and KO cells were mixed and plated to a 1:1 ratio in a 96-well plate with optically clear flat-bottom. Cells were stained with the indicated S1PR1 antibodies and with the corresponding Alexa-fluor 555 coupled secondary antibody including DAPI. Acquisition of the blue (nucleus-DAPI), green (identification of WT wells), red (antibody staining) and far-red (identification of KO cells) channels was performed. Representative images of the merged blue and red (grayscale) channels are shown. WT and KO cells are outlined with green and magenta dashed line, respectively. When an antibody was recommended for immunofluorescence by the supplier, we tested it at the recommended dilution. The rest of the antibodies were tested at 1 and 2 μg/ml and the final concentration was selected based on the detection range of the microscope used and a quantitative analysis not shown here. Antibody dilution used: ab233386** at 1/400, A12935 at 1/1000, ARP80838 at 1/250., NBP2-67129** at 1/1000, 63335** at 1/2000, 55133-1-AP at 1/500, MA5-32587** at 1/1000, MA5-35431** at 1/300, MA5-38484* at 1/200. Bars = 10 μm. *Monoclonal antibody, **Recombinant antibody.

In conclusion, we have screened nine S1PR1 commercial antibodies by western blot, immunoprecipitation, and immunofluorescence by comparing the signal produced by the antibodies in human SK-HEP-1 WT and S1PR1 KO cells. Several high-quality antibodies that successfully detect S1PR1 under our standardized experimental protocol can be identified. Researchers who wish to study S1PR1 in a different species are encouraged to select high-quality antibodies, based on the results of this study, and investigate the predicted species reactivity of the manufacturer before extending their research.

The underlying data for this study can be found on Zenodo, an open-access repository for which YCharOS has its own collection of antibody characterization reports.14,15

Methods

The standardized protocols used to carry out this KO cell line-based antibody characterization platform was established and approved by a collaborative group of academics, industry researchers and antibody manufacturers. The detailed materials and step-by-step protocols used to characterize antibodies in western blot, immunoprecipitation and immunofluorescence are openly available on Protocol Exchange, a preprint server (DOI: 10.21203/rs.3.pex-2607/v1).10

Antibodies and cell line used

Cell lines used and primary antibodies tested in this study are listed in Tables 1 and 2, respectively. To ensure that the cell lines and antibodies are cited properly and can be easily identified, we have included their corresponding Research Resource Identifiers, or RRID.16,17

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 11 Jul 2024
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Ayoubi R, Fotouhi M, Alende C et al. A guide to selecting high-performing antibodies for S1PR1 (UniProt ID: P21453) for use in western blot, immunoprecipitation, and immunofluorescence [version 1; peer review: 1 not approved]. F1000Research 2024, 13:792 (https://doi.org/10.12688/f1000research.153244.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 11 Jul 2024
Views
22
Cite
Reviewer Report 05 Aug 2024
Melissa Pitman, University of Adelaide, The University of Adelaide Faculty of Sciences (Ringgold ID: 98478), Adelaide, South Australia, Australia 
Not Approved
VIEWS 22
This paper used the WT and S1PR1 knockout SK-HEP-1 cells to evaluate the quality of the anti-S1PR1 antibodies obtained from different companies in three different applications, i.e. WB, IP, and IF. The results could be a useful guide for other ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Pitman M. Reviewer Report For: A guide to selecting high-performing antibodies for S1PR1 (UniProt ID: P21453) for use in western blot, immunoprecipitation, and immunofluorescence [version 1; peer review: 1 not approved]. F1000Research 2024, 13:792 (https://doi.org/10.5256/f1000research.168111.r302715)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 05 Sep 2024
    Kathleen Southern, Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, Canada
    05 Sep 2024
    Author Response
    Thank you to Melissa Pitman for your comprehensive review of this manuscript. The authors have taken great consideration from all suggested changes and made the necessary changes to ensure future ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 05 Sep 2024
    Kathleen Southern, Department of Neurology and Neurosurgery, Structural Genomics Consortium, The Montreal Neurological Institute, McGill University, Montreal, H3A 2B4, Canada
    05 Sep 2024
    Author Response
    Thank you to Melissa Pitman for your comprehensive review of this manuscript. The authors have taken great consideration from all suggested changes and made the necessary changes to ensure future ... Continue reading

Comments on this article Comments (0)

Version 3
VERSION 3 PUBLISHED 11 Jul 2024
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.